Curious?

We can send you Clearmind news via email.

Thank You

Your contact information has been received. We will send you additional information via email shortly.
Oops! Something went wrong while submitting the form.

Initiation of first in human clinical trial for alcohol use disorder  View press release.

Revolutionary Psychedelics for Treating Addiction & Mental Health

Clearmind Medicine develops breakthrough treatments for binge behaviour and mental health, including alcohol use disorder, binge eating and depression.

They Call it The Miracle

What if a novel psychedelic could be the solution to one of society's most complicated and expensive mental health issues: Alcohol Use Disorder?

Our First Indication

Alcohol Use Disorder

Over 57 million Americans report four or more episodes of heavy drinking per month...

... With an average of seven drinks per episode.1

Over 18 million Americans struggle with Alcohol Use Disorder2—the inability to reduce alcohol consumption
55% of victims of intimate partner violence report alcohol abuse by their abusive partner.3
Approximately half of all sexual assaults are committed by men who had been drinking alcohol.4
35% of parental child abuse offenders consumed either alcohol or drugs at the time of the incident.5
[1] Annual Total Binge Drinks Consumed by U.S. Adults, 2015. Am J Prev Med. 2018 Apr;54(4):486-496
[2] Key Substance Use and Mental Health Indicators in the United States: Results from  the 2017 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration, September 14, 2018
[3] Alcohol and Crime: An Analysis of National Data on the Prevalence of Alcohol Involvement in Crime, U.S. Department of Justice, 1998
[4] Alcohol and Sexual Assault, National Institute on Alcohol Abuse and Alcoholism, 2001; 25(1): 43-51
[5] U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics, 2005

The Economic Cost

Alcohol and substance abuse have a higher economic burden than heart disease, depression and other leading health problems.

$193 billion3

Substance Abuse

$249 billion2

Alcohol Abuse

[1] US DOJ 2011, Bouchery, Horwood, Sacks, Simon & Brewer, 2011; Mrazek, Hornberger, Altar, & Degliar, 2014.

[2] Sacks, J. J., Gonzales, K. R., Bouchery, E. E., Tomedi, L. E., & Brewer,R. D. (2015). 2010 national and state costs of excessive alcohol  consumption. American Journal of Preventive Medicine, 49(5), e73-e79.
[3] National Drug Intelligence Center. (2011). National drug threat assessment.  Washington, DC: U.S. Department of Justice.

The Competition

Large Market & Competitive Density

Our Solution

MEAI: A New Psychoactive Molecule

5-Methoxy-2-aminoindane, or "MEAI"

MEAI exerts a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages with potential to change the lives of millions who struggle to drink in moderation.

How MEAI Works

Mark Haden, Clearmind’s VP Business Development, describes the MEAI treatment experience.

View Full Interview

It’s the ‘enough’ switch. [MEAI] signals to the brain that it is satisfied, that it wants nothing.

—Ezekiel Golan, Special Advisor for Innovation and New Initiatives

Why MEAI is Different

A New and Unique Psychedelic Treatment

The information presented in this table is based solely on the Company’s own market research. Actual information may contradict the Company’s findings.
[1] https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/
[2] Carnicella S, He DY, Yowell QV, Glick SD, Ron D. Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration. Addict Biol. 2010 Oct;15(4):424-33. doi: 10.1111/j.1369-1600.2010.00251.x. PMID: 21040239; PMCID: PMC3783954.

Our Patents

A Portfolio of 19 Patent Families

Clearmind patents consist of 19 utility patent families owned by the company.
These include 31 granted patents.

Our Treatments

Proprietary Treatment Candidates

Our Team

An experienced public company leader and a skilled navigator of clinical trial processes, Dr. Zuloff-Shani is leading the Clearmind team.

Adi Zuloff-Shani, PhD

Dr. Adi Zuloff-Shani is a Biomedical Research and Development Executive with a vast experience with over 20 years of strategic and operational leadership in the healthcare industry and a deep understanding of therapeutics development in heavily regulated environments.

View Team

News Releases

1

April

2025

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
Read More
21

March

2025

Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S.
Read More
19

March

2025

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
Read More
View All

Join Us

Let's Make History

Information

Reason for Inquiry

Thank you for sending your contact information—your details have been received.

Oops! Something went wrong. Please try again.
CMND Price Today by TradingView
CWY Price Today by TradingView